OBJECTIVE: To determine differences in the immunohistochemical (IHC) expression of Bcl-2 protein and Ki-67 antigen in patients with prostatic cancer who underwent radical prostatectomy with or without neoadjuvant hormonal therapy. MATERIALS AND METHODS: Ki-67 antigen and Bcl-2 protein were detected by IHC using MIB-1 and Bcl-2 antibodies in prostatectomy specimens from 28 patients who received hormonal therapy before surgery (group 1) and 51 patients who did not (group 2). RESULTS: In group 2, the mean MIB-1 index increased with increasing grade of tumour, from 11.6% in low-grade to 24.7% in high-grade tumours (P = 0.002). Bcl-2 expression did not correlate with either tumour grade or stage. In group 1, there were no correlations between Bcl-2 expression or MIB-1 index and tumour grade or stage. More tumours in group 1 were Bcl-2-positive (16 of 28, 57%) than were tumours in group 2 (11 of 51, 22%; P = 0.003). The mean (SD) MIB-1 index of tumours in group 2 [15.6 (14.4)%], was significantly greater than that of tumours in group 2 [6.8 (7.5)%; P = 0.004]. CONCLUSIONS: These results indicate that Bcl-2 positivity is increased by androgen ablation therapy and conversely, that the proliferative activity of cancer cells is significantly reduced. The expression of Bcl-2 protein may play a role in the ability of prostate cancer cells to survive in an androgen-deprived environment.
OBJECTIVE: To determine differences in the immunohistochemical (IHC) expression of Bcl-2 protein and Ki-67 antigen in patients with prostatic cancer who underwent radical prostatectomy with or without neoadjuvant hormonal therapy. MATERIALS AND METHODS: Ki-67 antigen and Bcl-2 protein were detected by IHC using MIB-1 and Bcl-2 antibodies in prostatectomy specimens from 28 patients who received hormonal therapy before surgery (group 1) and 51 patients who did not (group 2). RESULTS: In group 2, the mean MIB-1 index increased with increasing grade of tumour, from 11.6% in low-grade to 24.7% in high-grade tumours (P = 0.002). Bcl-2 expression did not correlate with either tumour grade or stage. In group 1, there were no correlations between Bcl-2 expression or MIB-1 index and tumour grade or stage. More tumours in group 1 were Bcl-2-positive (16 of 28, 57%) than were tumours in group 2 (11 of 51, 22%; P = 0.003). The mean (SD) MIB-1 index of tumours in group 2 [15.6 (14.4)%], was significantly greater than that of tumours in group 2 [6.8 (7.5)%; P = 0.004]. CONCLUSIONS: These results indicate that Bcl-2 positivity is increased by androgen ablation therapy and conversely, that the proliferative activity of cancer cells is significantly reduced. The expression of Bcl-2 protein may play a role in the ability of prostate cancer cells to survive in an androgen-deprived environment.
Authors: Li-Yan Khor; Michelle Desilvio; Rile Li; Timothy J McDonnell; M Elizabeth H Hammond; William T Sause; Miljenko V Pilepich; Paul Okunieff; Howard M Sandler; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-11 Impact factor: 7.038
Authors: Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese Journal: Curr Mol Med Date: 2012-07-01 Impact factor: 2.222
Authors: Hongjuan Zhao; Alan Thong; Rosalie Nolley; Stephen W Reese; Jennifer Santos; Alexandre Ingels; Donna M Peehl Journal: J Transl Med Date: 2013-08-28 Impact factor: 5.531